|
|
Volumn , Issue , 2014, Pages 199-203
|
|
Where we were, where we are, where we are going: progress in multiple myeloma
a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
TUMOR MARKER;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
ANIMAL;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
FORECASTING;
GENETIC PREDISPOSITION;
GENETICS;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HISTORY;
HUMAN;
MORTALITY;
MULTIPLE MYELOMA;
ONCOLOGY;
PATHOLOGY;
PHENOTYPE;
RECURRENT DISEASE;
RISK FACTOR;
TIME;
TREATMENT OUTCOME;
TRENDS;
ANIMALS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHEMOTHERAPY, ADJUVANT;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
FORECASTING;
GENETIC PREDISPOSITION TO DISEASE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
MEDICAL ONCOLOGY;
MULTIPLE MYELOMA;
NEOADJUVANT THERAPY;
PHENOTYPE;
RECURRENCE;
RISK FACTORS;
TIME FACTORS;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84919342495
PISSN: None
EISSN: 15488756
Source Type: Journal
DOI: 10.14694/EdBook_AM.2014.34.199 Document Type: Article |
|
Times cited : (46)
|
|
References (0)
|